Two Sigma Investments Adds $25M in Aurinia Pharmaceuticals Inc. ($AUPH)
Two Sigma Investments significantly increased its holdings in Aurinia Pharmaceuticals, as per its latest 13F filing.
Key Points
- Two Sigma Investments increased its Aurinia Pharmaceuticals stake by 74.7%, adding 1,465,963 shares to total 3,428,705 shares, valued at $56.4 million.
- Aurinia Pharmaceuticals, trading at $16.46, has a market cap of $2.12 billion and a P/E ratio of 7.6, with a 52-week range between $7.29 and $16.88.
- Insiders, including CEO Kevin Tang, recently bought shares, while analysts have mixed ratings with targets ranging from $15 to $21.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Two Sigma Investments has significantly increased its stake in Aurinia Pharmaceuticals Inc. (NasdaqGM: AUPH). As per the latest 13F filing, Two Sigma boosted its holdings by 74.7%, adding 1,465,963 shares to its portfolio. This brings its total to 3,428,705 shares, valued at approximately $56.4 million as of the reporting period.
Two Sigma Investments vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Two Sigma Investments' Aurinia Pharmaceuticals Position
Two Sigma Investments made a substantial addition to its Aurinia Pharmaceuticals position, going from 1,962,742 shares to 3,428,705 shares. This increase of 1,465,963 shares represents a 74.7% uplift, reflecting a strong vote of confidence in the biotechnology company.
Other Institutional Activity in Aurinia Pharmaceuticals
TANG CAPITAL MANAGEMENT LLC also increased its stake in Aurinia Pharmaceuticals, adding 900,000 shares for a total of 12,229,500 shares worth about $181.2 million. Meanwhile, BLACKROCK, INC. slightly reduced its holdings by 82,608 shares, ending with 7,845,521 shares valued at approximately $116.3 million. NEA MANAGEMENT COMPANY, LLC maintained its position with 3,969,834 shares, valued at around $58.8 million. STATE STREET CORP added 25,107 shares, bringing its total to 2,527,099 shares, valued at $37.5 million.
Aurinia Pharmaceuticals Inc. Stock Up 5.3%
Shares of Aurinia Pharmaceuticals Inc. (NasdaqGM: AUPH) are trading at $16.46. The company boasts a market cap of $2.12 billion with a P/E ratio of 7.6. Its beta is 1.434, indicating moderate volatility. The stock's 52-week range has been between $7.29 and $16.88, with a 50-day moving average of $15.78 and a 200-day moving average of $14.58. Aurinia has a strong current ratio of 5.55 and a quick ratio of 4.95, with a debt-to-equity ratio of 12.09.
$AUPH stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Aurinia Pharmaceuticals reported revenue of $298.3 million, with a growth rate of 24.4%. The company achieved a net margin just shy of 100%, and a return on equity of 64.98%. Earnings per share stood at $2.16. The next earnings announcement is scheduled for July 30, 2026.
Insider Buying and Selling at Aurinia Pharmaceuticals Inc.
Recent insider activity at Aurinia Pharmaceuticals included several purchases. On June 4, 2026, insiders Jeffrey Allen Bailey, Craig Johnson, Kathleen Goetz, and Tina Susan Nova each acquired 23,931 shares. CEO Kevin Tang purchased 10,000 shares at $1.65 and another 206,005 shares at $15.28 on June 2, 2026.
Analysts Set New Price Targets
Analysts have mixed views on Aurinia Pharmaceuticals. On December 3, 2025, Leerink Partners downgraded the stock to a hold with a $16 price target. Meanwhile, Jefferies upgraded it to a buy with a target of $21 on November 7, 2025. RBC Capital downgraded it to a hold with a $15 target on November 5, 2025. The consensus target price is $17 from 7 analysts.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company based in Edmonton, Canada, specializing in treatments for autoimmune diseases. It is best known for LUPKYNIS, a therapy for lupus nephritis. The company also develops aritinercept, targeting B cell-activating factors for autoimmune conditions. Led by CEO Kevin C. Tang, Aurinia operates in the biotechnology sector, employing 128 people.
Bottom Line
Two Sigma Investments' increased stake in Aurinia Pharmaceuticals is a significant move, reflecting strong confidence in the company's growth potential. Investors often track such institutional changes as they can signal broader market sentiment. However, it's important to remember that 13F filings are historical snapshots and may not represent the current position.
Get Aurinia Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $AUPH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.